Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ASLAN Pharma Selects PharmaNet/i3 as Strategic Partner | Contract Pharma

What are you searching for?

Sign in
Breaking News

ASLAN Pharma Selects PharmaNet/i3 as Strategic Partner

Will support development of oncology portfolio in Asia

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ASLAN Pharmaceuticals has selected PharmaNet/i3 as a strategic partner to support the development of its oncology portfolio in Asia, and to conduct Phase I and Phase II trials for two of ASLAN’s compounds.
 
Dr. Alan Barge, ASLAN’s chief medical officer, said, “We chose to work with PharmaNet/i3 because of the commitment and passion shown by their team and the creative thinking they brought to our oncology development strategy. ASLAN is keen to build a strong strategic relationship with PharmaNet/i3, a company that shares our focus on quality and efficiency.”
  
“Clinical development of oncology therapeutics requires a special understanding of the mechanism of action and the different approaches to cancer therapies,” said Dalvir Gill, Ph.D., president of Phase II – IV Development at PharmaNet/i3. “ASLAN has a novel and creative approach to personalized medicine and combination therapy. We will work closely with ASLAN to address the unique methodologies needed to evaluate the efficacy and safety of their innovative products and look forward to a long and productive relationship.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics